newsfilter
← Latest News
GlobeNewswire·

Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update

MYQORZO® (aficamten) Net Product Revenue of $44.5 Million Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 and Type II Variation in the European Union in Early 2027 ~$1.6 Billion in